In TNM (Tumor, Node, Metastasis) classification and staging of breast cancer, what is the incorrect statement regarding fibroadenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fibroadenoma is NOT a Premalignant Lesion - Answer E is Incorrect

The incorrect statement is E: "Premalignant lesion." Fibroadenomas are benign breast tumors that do not represent premalignant lesions, though they may be associated with a slightly elevated risk of breast cancer in specific circumstances.

Understanding Fibroadenoma Classification

Fibroadenomas are benign breast tumors, not premalignant lesions, and this is a critical distinction in breast pathology 1. The term "premalignant" implies a lesion that will progress to cancer if left untreated, which is fundamentally incorrect for fibroadenomas.

Why the Other Statements Are Correct

A. Mostly Benign - CORRECT

  • Fibroadenomas are definitively benign breast lesions, representing one of the most common causes of benign breast lumps in premenopausal women 1
  • The consensus view confirms that women with fibroadenomas are not at significant increased risk of developing breast cancer 1

B. Mostly Mobile - CORRECT

  • Fibroadenomas are characteristically mobile on clinical examination, which is a classic distinguishing feature from malignant lesions
  • This mobility reflects their well-circumscribed, encapsulated nature

C. Diagnosis by Mammogram - CORRECT

  • Diagnosis is based on the combination of clinical examination, imaging (mammography combined with ultrasound in older women, ultrasound alone in younger women), and non-surgical tissue biopsy (the triple test) 1
  • However, a clinical diagnosis of fibroadenoma alone is unreliable and does not exclude malignancy even in younger women 1

D. May Be Huge - CORRECT

  • Fibroadenomas can vary considerably in size, and giant fibroadenomas (>5 cm) are well-documented entities
  • Size variation is a recognized characteristic of these benign tumors

The Critical Distinction: Risk Factor vs. Premalignant

While fibroadenomas are not premalignant, certain subtypes do carry an elevated cancer risk:

  • Simple fibroadenomas without hyperplasia: Relative risk 1.48-1.7 for subsequent breast cancer 2
  • Complex fibroadenomas (with cysts, sclerosing adenosis, epithelial calcifications, or papillary apocrine changes): Relative risk 3.10 2
  • Fibroadenomas with adjacent proliferative disease: Relative risk 3.88 2
  • Complex fibroadenomas with family history: Relative risk 3.72 2

Importantly, two-thirds of patients with noncomplex fibroadenomas and no family history of breast cancer do not have an increased risk 2.

Clinical Pitfalls to Avoid

  • Never assume all fibroadenomas are zero-risk: While not premalignant, complex fibroadenomas and those with hyperplasia require more careful management 3
  • Beware in postmenopausal women: Breast cancer can mimic fibroadenoma on imaging in this population, necessitating thorough tissue sampling with both FNA and core biopsy 4
  • Monitor for changes: When new suspicious features develop in a known fibroadenoma, proceed with diagnostic workup as breast cancer can arise adjacent to involuting fibroadenomas 5
  • Triple assessment is mandatory: Clinical diagnosis alone is unreliable and does not exclude malignancy 1

References

Research

Fibroadenoma of the breast.

The Medical journal of Australia, 2001

Research

Long-term risk of breast cancer in women with fibroadenoma.

The New England journal of medicine, 1994

Research

Breast cancer mimicking fibroadenomas in postmenopausal women.

International journal of surgery (London, England), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.